Tremfya Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage Patient Counseling Information MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Guselkumab

Indications/Uses

Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Active psoriatic arthritis in adult patients who have had inadequate response or who have been intolerant to prior DMARD therapy. Moderate to severe palmoplantar pustulosis in adult patients who inadequately respond to conventional therapy.

Click to view Tremfya detailed prescribing information

Dosage/Direction for Use

Plaque psoriasis & palmoplantar pustulosis 100 mg SC inj at wk 0, wk 4 & every 8 wk thereafter. Psoriatic arthritis 100 mg SC inj at wk 0 & 4, followed by maintenance dose every 8 wk. Patient at high risk of joint damage 100 mg every 4 wk may be considered.

Click to view Tremfya detailed prescribing information

Overdosage

View Tremfya overdosage for action to be taken in the event of an overdose.

Contraindications

Serious hypersensitivity.

Click to view Tremfya detailed prescribing information

Special Precautions

Discontinue use if hypersensitivity reactions occur. Infections, do not initiate in patients w/ any clinically important active infection. Pre-treatment evaluation for TB. Immunizations, to complete all age-appropriate immunizations prior to initiating therapy. Hepatic transaminase elevations, to evaluate liver enzymes at baseline & thereafter according to routine patient management. Pregnancy & lactation. Ped <18 yr.

Click to view Tremfya detailed prescribing information

Use In Pregnancy & Lactation

Click to view Tremfya detailed prescribing information

Adverse Reactions

Resp tract infections. Increased transaminases; headache; diarrhea; arthralgia; inj site erythema & reactions.

Click to view Tremfya detailed prescribing information

Drug Interactions

Concomitant use w/ CYP450 substrate. Not to be given concurrently w/ live vaccines.

Click to view Tremfya detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Tremfya detailed prescribing information

Storage

View Tremfya storage conditions for details to ensure optimal shelf-life.

Description

View Tremfya description for details of the chemical structure and excipients (inactive components).

Action

View Tremfya mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Immunosuppressants / Psoriasis, Seborrhea & Ichthyosis Preparations

ATC Classification

L04AC16 - guselkumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.

Regulatory Classification

Patient Counseling Information

View Tremfya patient counselling information

Presentation/Packing

Form

Tremfya soln for inj (pre-filled pen) 100 mg/mL

Packing/Price

1's

Form

Tremfya soln for inj (pre-filled syringe) 100 mg/mL

Packing/Price

1's

Tremfya

guselkumab

Manufacturer:

Janssen

Distributor:

Zuellig Pharma